Moderna, Inc. Increase (Decrease) in Accrued Liabilities
Moderna, Inc. (MRNA) reported Increase (Decrease) in Accrued Liabilities of $475.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $11.00M.
- Moderna, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $464.00M.
- Moderna, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $194.00M, a 546.67% increase year-over-year.
- Moderna, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $199.00M, a 306.12% increase year-over-year.
- Moderna, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.00M.
- Moderna, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$385.00M.
- Moderna, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$340.00M, a 155.56% decline from fiscal 2022.
- Moderna, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $612.00M, a 38.12% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $475.00M 10-Q · filed 2026-07-31 | $669.00M derived: sum of 3 quarters · filed 2026-07-31 | $868.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $464.00M 10-Q · filed 2026-05-01 | $658.00M derived: sum of 2 quarters · filed 2026-05-01 | $857.00M derived: sum of 3 quarters · filed 2026-05-01 | $843.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $194.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $393.00M derived: sum of 2 quarters · filed 2026-02-20 | $379.00M derived: sum of 3 quarters · filed 2026-07-31 | -$2.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $199.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $185.00M derived: sum of 2 quarters · filed 2026-07-31 | -$196.00M 10-Q · filed 2025-11-06 | -$166.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$395.00M 10-Q · filed 2026-07-31 | -$365.00M derived: sum of 3 quarters · filed 2026-07-31 | -$316.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$381.00M 10-Q · filed 2026-05-01 | -$351.00M derived: sum of 2 quarters · filed 2026-05-01 | -$302.00M derived: sum of 3 quarters · filed 2026-05-01 | -$368.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $79.00M derived: sum of 2 quarters · filed 2026-02-20 | $13.00M derived: sum of 3 quarters · filed 2026-02-20 | -$385.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$17.00M derived: sum of 2 quarters · filed 2025-11-06 | -$415.00M 10-Q · filed 2025-11-06 | -$818.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | -$66.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$464.00M 10-Q · filed 2025-08-01 | -$867.00M derived: sum of 3 quarters · filed 2026-02-20 | -$171.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$398.00M 10-Q · filed 2025-05-01 | -$801.00M derived: sum of 2 quarters · filed 2026-02-20 | -$105.00M derived: sum of 3 quarters · filed 2026-02-20 | -$243.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$403.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $293.00M derived: sum of 2 quarters · filed 2026-02-20 | $155.00M derived: sum of 3 quarters · filed 2026-02-20 | -$340.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $696.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $558.00M derived: sum of 2 quarters · filed 2024-11-07 | $63.00M 10-Q · filed 2024-11-07 | $321.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$138.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$633.00M 10-Q · filed 2024-08-01 | -$375.00M derived: sum of 3 quarters · filed 2025-02-21 | -$326.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$495.00M 10-Q · filed 2024-05-02 | -$237.00M derived: sum of 2 quarters · filed 2025-02-21 | -$188.00M derived: sum of 3 quarters · filed 2025-02-21 | $3.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $258.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $307.00M derived: sum of 2 quarters · filed 2025-02-21 | $498.00M derived: sum of 3 quarters · filed 2025-02-21 | $612.00M 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $240.00M derived: sum of 2 quarters · filed 2023-11-03 | $354.00M 10-Q · filed 2023-11-03 | $743.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $191.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $305.00M 10-Q · filed 2023-08-03 | $694.00M derived: sum of 3 quarters · filed 2024-02-23 | $927.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $114.00M 10-Q · filed 2023-05-04 | $503.00M derived: sum of 2 quarters · filed 2024-02-23 | $736.00M derived: sum of 3 quarters · filed 2024-02-23 | $818.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $389.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $622.00M derived: sum of 2 quarters · filed 2024-02-23 | $704.00M derived: sum of 3 quarters · filed 2024-02-23 | $989.00M 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $233.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $315.00M derived: sum of 2 quarters · filed 2022-11-03 | $600.00M 10-Q · filed 2022-11-03 | $856.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $82.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $367.00M 10-Q · filed 2022-08-03 | $623.00M derived: sum of 3 quarters · filed 2023-02-24 | $735.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $285.00M 10-Q · filed 2022-05-04 | $541.00M derived: sum of 2 quarters · filed 2023-02-24 | $653.00M derived: sum of 3 quarters · filed 2023-02-24 | $685.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $256.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $368.00M derived: sum of 2 quarters · filed 2023-02-24 | $400.00M derived: sum of 3 quarters · filed 2023-02-24 | $388.00M 10-K · filed 2023-02-24 | $388.39M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $112.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $144.00M derived: sum of 2 quarters · filed 2021-11-04 | $132.00M 10-Q · filed 2021-11-04 | $132.37M 10-Q · filed 2020-10-30 | $137.25M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $20.00M 10-Q · filed 2021-08-05 | $20.19M 10-Q · filed 2020-08-06 | $25.25M derived: sum of 3 quarters · filed 2022-02-25 | $44.80M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | -$12.00M 10-Q · filed 2021-05-06 | -$12.95M 10-Q · filed 2020-05-07 | -$6.75M derived: sum of 2 quarters · filed 2022-02-25 | $12.80M derived: sum of 3 quarters · filed 2022-02-25 | $17.56M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $24.80M derived: sum of 2 quarters · filed 2022-02-25 | $29.56M derived: sum of 3 quarters · filed 2022-02-25 | -$3.00M 10-K · filed 2022-02-25 | -$3.36M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $19.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $24.30M derived: sum of 2 quarters · filed 2020-10-30 | -$8.25M 10-Q · filed 2020-10-30 | $17.72M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$27.80M 10-Q · filed 2020-08-06 | -$1.82M derived: sum of 3 quarters · filed 2021-02-26 | $5.95M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | -$32.56M 10-Q · filed 2020-05-07 | -$6.58M derived: sum of 2 quarters · filed 2021-02-26 | $1.19M derived: sum of 3 quarters · filed 2021-02-26 | $13.26M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $25.98M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $33.75M derived: sum of 2 quarters · filed 2021-02-26 | $45.82M derived: sum of 3 quarters · filed 2021-02-26 | $8.79M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $7.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $19.84M derived: sum of 2 quarters · filed 2019-11-06 | -$17.19M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $12.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$24.96M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$37.03M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $34.37M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $5.33M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |